# A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

> **NCT03963232** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 520 (actual)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Galcanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03963232
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2021-07-27
- **Final completion:** 2022-03-11
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963232, "A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03963232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*